INDIVA Stock (TSXV: NDVA) (OTC: NDVAF) - Investor Dashboard


➔ INDIVA
TSXV Ticker: NDVA
OTC Ticker: NDVAF
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 27
Established: 2015
CEO: Niel Marotta

Summary

Fiscal Year-End: December
Facilities: 1
Dried Flower: Production
Extracts: No
Number of Patients: N/A
Headquarters: London, ON

Financials (06/30/18)

Cash on hand: $27.3mm
Fixed Investment: $5.7mm
Shareholders’ Equity: $32.2mm
Revenues – Last Quarter: $0K
Adj. Gross Margin : na
EPS : -.03

Capital Structure (08/29/18)

Last Financing: 14.24mm Units at $1.05
Basic Shares: 81.0mm
Warrants: 27.3mm
Options: 4.5mm
Diluted Shares: 121.7mm

Company Brief

INDIVA, based in London, Ontario, is focused on providing medical-grade cannabis to medical and adult-use clients, both domestically and internationally. With an internationally recognized and award-winning grow team, GMP-compliant standard operating procedures, and high-quality, medical-grade cannabis. INDIVA officially began trading on the TSXV on December 19, 2017.

The company’s sales license is imminent, with sales expected to start in Q4 of 2018, and INDIVA has a fully funded expansion to 40,000 sq. ft. underway and to be completed in Q4 of 2018. Additionally, a fully funded processing facility is planned for 2019. The facility will produce INDIVA, Bhang, DeepCell and other cannabis products.

Featured Video


INDIVA High Quality Products

Bhang Powered by INDIVA

DeepCell Powered by INDIVA


Highlights

  • Sales license is imminent, with sales expected to start in Q4 of 2018
  • Strategic partnerships and investments with U.S. branded companies
  • Large cash balance that exceeds intermediate-term capital needs
  • Highly regarded master grower and an experienced management team

Growth Strategy

  • Fully funded expansion to 40,000 sq. ft. to be completed in Q4 of 2018
  • Fully funded processing facility planned for 2019
  • Evaluating 3 large greenhouse facilities in S.W. Ontario for production partnerships
  • Active negotiations with German distributors and with Polish, Costa Rican and Maltese governments for production partnerships

Differentiators

  • State-of-the-art GMP-standard indoor production facility
  • Agreement with London Compassion Society to transfer up to 1,200 clients
  • Strong ties to London’s medical community
  • Investments in U.S. brands Bhang and Deepcell Industries with in-licensing for Canadian market

Institutional Analyst Coverage


Curated Stories & News


Visit INDIVA.
at www.indiva.com

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. INDIVA is a client of NCV Media, LLC. Read our full disclaimer.